The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
D-type cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation. Inhibitors of CDK4 and CDK6 are currently being tested in clinical trials for patients with several cancer types, with promising results. Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2. This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways. Inhibition of cyclin D3-CDK6 in tumour cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione. This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumour cells. The pro-survival function of cyclin D-associated kinase operates in tumours expressing high levels of cyclin D3-CDK6 complexes. We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumour subsets that undergo cell death and tumour regression upon inhibition of CDK4 and CDK6. Cyclin D3-CDK6, through its ability to link cell cycle and cell metabolism, represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The cyclin D3/CDK6 kinase complex can phosphorylate 6-phosphofructokinase and pyruvate kinase M2 (Wang et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“This has the effect of pushing glycolytic intermediates into the pentose phosphate and serine pathways, and inhibition of CDK6 (through treatment with palbociclib, ribociclib, or knockdown of CDK6) depletes the antioxidants NADPH and glutathione, increasing ROS and apoptosis.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“These cells express very low levels of cyclin D1, cyclin D2, and CDK4, and the proliferative decision is dependent upon cyclin D3 and CDK6 (Wang et al., 2017; Wolowiec et al., 1996).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Self-citationThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
A tissue-specific atlas of mouse protein phosphorylation and expression
Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villén, J., Haas, W., Sowa, M. E., & Gygi, S. P. (2010) · Cell · doi:10.1016/j.cell.2010.12.001 · Cited by 1,778
Self-citationMalumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., & Gygi, S. P. (2006) · Nature Biotechnology · doi:10.1038/nbt1240 · Cited by 1,577
Self-citationGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Self-citationAnastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Quantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114
Cited by
Items 101–200 of 345
Ding, J., Wang, Q., Guo, N., Wang, H., Chen, H., Ni, G., & Li, P. (2020) · Aging · doi:10.18632/aging.103668 · Cited by 45
“oncogene that was upregulated and in a series of adenocarcinomas, including such as in breast cancer and non-small cell lung cancer [32, 33].”
BackgroundSelf-citationOut of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis
Cheung, A. H. K., Hui, C. H., Wong, K. Y., Liu, X., Chen, B., Kang, W., & To, K. F. (2022) · International Journal of Cancer · doi:10.1002/ijc.34288 · Cited by 52
“also inhibit the enzyme 6-phosphofructokinase and lead to the shunting of intermediates to PPP.(36,56) Whether the regulation of CDK4 on cancer metabolism is predominantly exerted by its direct effect or via”
BackgroundInfluentialWang, F., Demir, S., Gehringer, F., Osswald, C. D., Seyfried, F., Enzenmüller, S., Eckhoff, S. M., Maier, T. H. P., Holzmann, K., Debatin, K., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813576 · Cited by 46
Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
Pennycook, B. R., & Barr, A. R. (2021) · Open Biology · doi:10.1098/rsob.210125 · Cited by 49
Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus
Wan, Q., Tavakoli, L., Wang, T., Tucker, A. J., Zhou, R., Liu, Q., Feng, S., Choi, D., He, Z., Gack, M. U., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45852-5 · Cited by 42
“The cyclin D3-CDK6 complex has been shown to reprogram glycolysis, which ultimately favors the pentose phosphate pathways (PPP) and serine biosynthesis, thereby removing reactive oxygen species in human T cell acute lymphoblastic leukemia (T-ALL) cells 58 .”
BackgroundLorito, N., Bacci, M., Smiriglia, A., Mannelli, M., Parri, M., Comito, G., Ippolito, L., Giannoni, E., Bonechi, M., Benelli, M., et al. (2020) · Cells · doi:10.3390/cells9030668 · Cited by 45
“It has been reported previously that the cyclin D1-CDK4 and cyclin D3-CDK6 pairs can regulate glucose metabolism [10,12] and that palbociclib administration reduces glucose metabolism in triple negative breast cancer in vitro models [34].”
BackgroundOncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia
Tan, T. K., Zhang, C., & Sanda, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2518-z · Cited by 44
Rodríguez, C., Puente‐Moncada, N., Reiter, R. J., Sánchez‐Sánchez, A. M., Herrera, F., Rodríguez‐Blanco, J., Duarte‐Olivenza, C., Turos‐Cabal, M., Antolín, I., & Martín, V. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29886 · Cited by 44
“As an example, hypoxia and cyclin D3/CDK6 complex inhibit PFK1 (H. Wang et al., 2017), and ROS and CDK6 inhibit PK in cancer cells (Anastasiou et al., 2011), thereby decreasing glycolysis and redirecting carbon flux to the PPP.”
BackgroundFan, L., Du, P., Li, Y., Chen, X., Liu, F., Liu, Y., Petrov, A. M., Li, X., Wang, Z., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c10142 · Cited by 47
Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer
Wang, Z., Gao, J., Zhou, J., Liu, H., & Xu, C. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e26 · Cited by 40
“Cyclin D3 is an important regulatory factor in cell cycle, combine with cyclin-dependent kinases (CDK4 and CDK6) to compose the core cell cycle machinery that drives cell proliferation [29].”
BackgroundSitthideatphaiboon, P., Teerapakpinyo, C., Korphaisarn, K., Leelayuwatanakul, N., Pornpatrananrak, N., Poungvarin, N., Chantranuwat, P., Shuangshoti, S., Aporntewan, C., Chintanapakdee, W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06239-y · Cited by 41
Wu, X., Li, Q., Feng, Y., & Ji, Q. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/2313021 · Cited by 37
“D-type cyclins are typical targets and crucial signaling molecules for cancer treatment [64].”
BackgroundKnudsen, E. S., Shapiro, G. I., & Keyomarsi, K. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281085 · Cited by 39
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 37
Xu, Y., Lai, H., Pan, S., Pan, L., Liu, T., Yang, Z., Chen, T., & Zhu, X. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122452 · Cited by 39
Wang, Y., Chen, X., Yan, Y., Zhu, X., Liu, M., & Liu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02121 · Cited by 36
How selective are clinical CDK4/6 inhibitors?
Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 38
“Conversely, in cell lines not expressing appreciable levels of CDK6 and cyclin D3, such as breast cancer cells, CDK4/6 inhibition did not reduce the catalytic activity of PFK1 and PKM2 and the cells only underwent cell cycle arrest.(25,78,79)”
BackgroundThe role of CDK4/6 inhibitors in early breast cancer
Gil‐Gil, M., Alba, E., Gavilá, J., de la Haba-Rodríguez, J., Ciruelos, E. M., Tolosa, P., Candini, D., & Llombart‐Cussac, A. (2021) · The Breast · doi:10.1016/j.breast.2021.05.008 · Cited by 37
Metabolic Remodeling as a Way of Adapting to Tumor Microenvironment (TME), a Job of Several Holders
Serpa, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_1 · Cited by 36
García-Domínguez, E., Carretero, A., Viña-Almunia, A., Doménech, J., González, G. O., Viña, J., & Gómez‐Cabrera, M. C. (2022) · Cells · doi:10.3390/cells11193041 · Cited by 36
Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Fang, H., Huang, D., Yang, F., & Guan, X. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4612-y · Cited by 36
“As a consequence, measuring the level of cyclin D3-CDK6 in cancer cells may help identify tumor subsets that undergo cell death and tumor regression after using CDK4/6 inhibitors, thus to detect tumor recurrence or drug resistance timely in clinical practice [36].”
BackgroundYousuf, M., Shamsi, A., Khan, S., Κhan, P., Shahwan, M. J., Elasbali, A. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.06.013 · Cited by 34
PFKP: More than phosphofructokinase
Wang, H., Penaloza, T., Manea, A. J., & Gao, X. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.001 · Cited by 33
Self-citationThe RUNX1/RUNX1T1 network: translating insights into therapeutic options
Swart, L. E., & Heidenreich, O. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.005 · Cited by 36
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
Bloedjes, T. A., de Wilde, G., & Guikema, J. E. J. (2021) · Cancers · doi:10.3390/cancers13030396 · Cited by 35
CDK4/6 blockade in breast cancer: current experience and future perspectives
Zardavas, D., Ponde, N. F., & Tryfonidis, K. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389896 · Cited by 35
“Interestingly, the acquired CDK6 amplification resulted also in reduced ER/PgR expression, and thus reduced sensitivity to endocrine treatment [79].”
BackgroundInfluentialMitchell, K. G., Amini, B., Wang, Y., Carter, B. W., Godoy, M. C. B., Parra, E. R., Behrens, C., Villalobos, P. A., Reuben, A., Lee, J. J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02560-5 · Cited by 34
Huang, W., Abudureheman, T., Xia, J., Chu, L., Zhou, H., Zheng, W., Zhou, N., Shi, R., Li, M., Zhu, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641271 · Cited by 35
“CDKs affect the catalytic activity of metabolic rate-enzymes and modulate the cell cycle arrest and apoptosis of tumor cells (Wang et al., 2017; Icard et al., 2019).”
BackgroundCell Cycle Entry Control in Naïve and Memory CD8+ T Cells
Lewis, D. A., & Ly, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727441 · Cited by 36
Division enzyme regulates metabolism
Krall, A. S., & Christofk, H. R. (2017) · Nature · doi:10.1038/nature22504 · Cited by 33
Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer
Heylen, E., Verstraete, P., Aerschot, L. V., Geeraerts, S. L., Venken, T., Timcheva, K., Nittner, D., Verbeeck, J., Royaert, J., Gijbels, M. J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02216-y · Cited by 34
“Blocking these enzymes enables the leukaemic cells to redirect glycolytic intermediates into the pentose phosphate (PPP) and serine pathway to supply the cells with GSH and NADPH [46].”
BackgroundItkonen, H. M., Poulose, N., Walker, S., & Mills, I. G. (2019) · Neoplasia · doi:10.1016/j.neo.2019.05.001 · Cited by 30
“In addition, CDK4 and CDK6, regulators of the G1-S transition, can also directly regulate glucose metabolism [10,11].”
BackgroundWhole-Genome Methylation Analysis Reveals Epigenetic Variation in Cloned and Donor Pigs
Wang, M., Feng, S., Ma, G., Miao, Y., Zuo, B., Ruan, J., Zhao, S., Wang, H., Du, X., & Liu, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00023 · Cited by 30
Self-citationTherapeutic potential of CDK4/6 inhibitors in renal cell carcinoma
Sager, R., Backe, S. J., Ahanin, E. F., Smith, G., Nsouli, I. S., Woodford, M. R., Bratslavsky, G., Bourboulia, D., & Mollapour, M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00571-8 · Cited by 29
Carpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Pan‐Castillo, B., Fafián‐Labora, J., Mitchell, T. P., Yuste, A., Öğrünç, M., Nightingale, T. D., Mayán, M. D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04569-3 · Cited by 32
Li, Z., Tang, X., Luo, Y., Chen, B., Zhou, C., Wu, X., Tang, Z., Qi, X., Cao, G., Hao, J., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28278 · Cited by 31
“The synthesis of NK007 was performed as described in our previous study (K. Wang et al., 2010) and its chemical structure is shown in Figure 1a.”
MethodMultiple Layers of Phospho-Regulation Coordinate Metabolism and the Cell Cycle in Budding Yeast
Zhang, L., Winkler, S., Schlottmann, F. P., Kohlbacher, O., Elias, J. E., Skotheim, J. M., & Ewald, J. C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00338 · Cited by 28
Coroglaucigenin induces senescence and autophagy in colorectal cancer cells
Huang, Y., Lei, J., Yi, G., Huang, F., Li, Y., Wang, C., Sun, Y., Dai, H., & Tan, G. (2018) · Cell Proliferation · doi:10.1111/cpr.12451 · Cited by 29
Gassaway, B. M., CARDONE, R. L., Padyana, A. K., Petersen, M. C., Judd, E. T., Hayes, S., Tong, S., Barber, K. W., Apostolidi, M., Abulizi, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.009 · Cited by 27
“Previous work has shown that CDK6 is able to phosphorylate and inhibit phosphofructokinase to decrease the levels of FBP, as well as directly phosphorylate and inhibit PKM2 (at a different, nonhomologous site to PKL) to regulate glycolytic flux (Wang et al., 2017); glucagon and PKA may work through a similar mechansim…”
BackgroundZhang, L., Zhao, G., Ji, S., Yuan, Q., & Zhou, H. (2020) · Medical Science Monitor · doi:10.12659/msm.921594 · Cited by 28
“Inhibitors of CDK6 show promise in cancer treatment [32].”
BackgroundChatterboxes: the structural and functional diversity of cyclins
Tatum, N. J., & Endicott, J. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.021 · Cited by 31
Lalonde, M., Sasseville, M., Gélinas, A.-M., Milanese, J., Béland, K., Drouin, S., Haddad, É., & Marcotte, R. (2022) · Haematologica · doi:10.3324/haematol.2022.280786 · Cited by 30
“45 Cyclin D3-CDK6 kinase regulates the switch from glycolysis to the PPP by directly phosphorylating and inhibiting key enzymes, which catalyze key rate-limiting steps in the glycolysis cascade such as 6-phosphofructokinase (PFK1), pyruvate kinase M2 (PKM2), but also GPI, PGK1, ENO1, and PKM.…”
BackgroundRen, X., Zhuang, H., Zhang, Y., & Zhou, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02125-5 · Cited by 31
Tanaka, Y., Momose, S., Tabayashi, T., Sawada, K., Yamashita, T., Higashi, M., Sagawa, M., Tokuhira, M., Rosenwald, A., Kizaki, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14286 · Cited by 30
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma
Yao, Y., Ng, J. F., Park, W. D., Samur, M., Morelli, E., Encinas, J., Chyra, Z., Xu, Y., Derebail, S., Epstein, C. B., et al. (2023) · Blood · doi:10.1182/blood.2022018885 · Cited by 42
Wekking, D., Leoni, V. P., Lambertini, M., Dessì, M., Pretta, A., Cadoni, A., Atzori, L., Scartozzi, M., & Solinas, C. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.10.001 · Cited by 28
Raimondi, L., Raimondi, F. M., Pietranera, M., Rocco, A. D., Benedetto, L. D., Miele, E., Lazzeroni, R., Cimino, G. G., & Spinelli, G. P. (2021) · Cancers · doi:10.3390/cancers13081928 · Cited by 26
“showed that nearly 85% of breast cancer cells have a normal Rb status, ruling out Rb from predictive resistance biomarkers [23].”
BackgroundLanceta, L., O’Neill, C. H., Lypova, N., Li, X., Rouchka, E. C., Waigel, S. J., Gómez-Gutiérrez, J. G., Chesney, J. A., & Imbert-Fernandez, Y. (2020) · Genes · doi:10.3390/genes11040467 · Cited by 27
“in cancer, whereas cyclin D3-CDK6 can directly phosphorylate and inhibit the activity of two key enzymes in the glycolyti path ay [23,24].”
BackgroundPalbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells
Conroy, L. R., Lorkiewicz, P., He, L., Yin, X., Zhang, X., Rai, S. N., & Clem, B. F. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01357-x · Cited by 27
Zhang, X., Sun, Y., Cheng, S., Yao, Y., Hua, X., Shi, Y., Jin, X., Pan, J., Hu, M. G., Ying, P., et al. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2039981 · Cited by 26
“Moreover, CDK6 may interact with mTOR as in T-ALL cells [13] and activates its activity.”
BackgroundInfluentialMetabolic oscillations during cell-cycle progression
Icard, P., & Simula, L. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.04.006 · Cited by 26
Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?
Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 34
Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics
Yousuf, M., Shamsi, A., Mohammad, T., Azum, N., Alfaifi, S., Asiri, A. M., Elasbali, A. M., Islam, A., Hassan, M. I., & Haque, Q. M. R. (2022) · ACS Omega · doi:10.1021/acsomega.2c03479 · Cited by 25
Yang, K., Zhang, X., Chen, L., Chen, S., & Ji, Y. (2021) · Cell Division · doi:10.1186/s13008-020-00069-y · Cited by 24
“However, the cyclin D3–cyclin-dependent kinase 6 (CDK6) complex can inhibit the catalytic activity of PFK-1 in the glycolytic pathway, suggesting a direct link between the cell cycle and cell metabolism [42].”
BackgroundAPC/C-CDH1–Regulated IDH3β Coordinates with the Cell Cycle to Promote Cell Proliferation
Wu, Q., Zhang, W., Xue, L., Wang, Y., Fu, M., Ma, L., Song, Y., & Zhan, Q.-M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2341 · Cited by 22
EphA2 promotes tumorigenicity of cervical cancer by up‐regulating CDK6
Huang, C., Chen, Z., He, Y., He, Z., Ban, Z., Zhu, Y., Ding, L., Chen, Y., Jeong, J.-H., Yuan, W., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16337 · Cited by 22
Chen, X., Wang, L., Hong, L., Su, Z., Zhong, X., Zhou, H., Zhang, X., Wu, J., & Shao, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.661988 · Cited by 22
“Cyclins and cyclin-dependent kinases (CDKs) are often involved in the majority of metabolic processes, such as glucose metabolism (Lee et al., 2014; Wang et al., 2017), lipogenesis (Zhao et al., 2012), amino acidmetabolism (Tarrado-Castellarnau et al., 2017), and mitochondrial activity (Hydbring et…”
BackgroundCCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia
Ketzer, F., Abdelrasoul, H., Vogel, M., Marienfeld, R. B., Müschen, M., Jumaa, H., Wirth, T., & Ushmorov, A. (2022) · Oncogenesis · doi:10.1038/s41389-021-00377-0 · Cited by 23
“In T-ALL, upregulation of CCND3 after treatment with palbociclib was also observed, albeit not further explained [24].”
The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance
Wang, M., Liu, J., Liao, X., Yi, Y., Xue, Y., Yang, L., Cheng, H.-L. M., & Liu, P. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102931 · Cited by 22
“Recent studies have indicated that CDK4/6 inhibitors display anti-tumor activities beyond simply enforcing growth inhibitory effects including tumor metabolism [37,56].”
BackgroundMethodBattisti, N. M. L., Kingston, B., King, J. P., Denton, A. S., Waters, S. H., Sita-Lumsden, A. R., Rehman, F. L., Stavraka, C., Kristeleit, H., Sawyer, E. J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05134-x · Cited by 22
Chen, M., Li, S., Liang, Y., Zhang, Y., Luo, D., & Wang, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656509 · Cited by 24
Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy
Liu, Y., Park, S., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17121941 · Cited by 21
“The cyclin D3/CDK6 kinase complex phosphorylates 6-phosphofructokinase and pyruvate kinase M2, which are key steps in glycolysis [121].”
Falco, P. D., Lazzarino, G., Felice, F., Desideri, E., Castelli, S., Salvatori, I., Ciccarone, F., & Ciriolo, M. R. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102585 · Cited by 22
“The same occurs after phosphorylation of PKM2 serine residues by CDK6 [46] or following cysteine oxidation due to a burst of oxidative stress [47].”
BackgroundBelapurkar, R., Pfisterer, M., Dreute, J., Werner, S., Zukunft, S., Fleming, I., Kracht, M., & Schmitz, M. L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06012-7 · Cited by 22
Triclosan down-regulates fatty acid synthase through microRNAs in HepG2 cells
Sun, D., Zhao, T., Long, K., Wu, M., & Zhang, Z. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174261 · Cited by 21
Patel, J., Gao, X., & Wang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087201 · Cited by 23
“Our previous study showed that cyclin D3 and CDK6 are highly expressed in T-ALL [17].”
BackgroundMethodSelf-citationEffect of disease progression on the podocyte cell cycle in Alport Syndrome
Nicolas, C., Hou, X., Petrosyan, A., Villani, V., Zhao, R., Hansen, J., Clair, G., Salem, F. E., Filippo, R. E. D., Cravedi, P., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.08.026 · Cited by 20
Liskova, V., Kajsik, M., Chovancova, B., Roller, L., & Križanová, O. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13401 · Cited by 20
In silico identification of novel CDK4 inhibitors for retinoblastoma
Kumar, M., Srivastava, V., Devi, U., Nackwal, K., Ahmed, M. Z., & Shukla, P. (2024) · Chemical Physics Impact · doi:10.1016/j.chphi.2024.100743 · Cited by 18
T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo
Klein, K., Witalisz‐Siepracka, A., Gotthardt, D., Agerer, B., Sternberg, F., Grausenburger, R., Knab, V. M., Bergthaler, A., & Sexl, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650977 · Cited by 19
“In line, CDK6 has previously been reported to regulate tumor cell metabolism in a kinase-dependent manner (38, 41).”
BackgroundJiang, Y. P., Wang, T., Sheng, D., Han, C., Tian, X., Zhang, P., You, W., Fan, W., Zhang, Z., Jin, T., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102561 · Cited by 18
“(2022) 298(11) 102561 chromatography were carried out using amylose resin following the manufacturer’s instructions (Transgene, #DP201-01).”
BackgroundMethodInfluentialZhang, X., Hou, X. S., Xu, C., Cheng, S., Ni, X., Shi, Y., Yao, Y., Chen, L., Hu, M. G., & Xia, D. (2023) · Food & Function · doi:10.1039/d3fo00613a · Cited by 19
Wang, L., Wu, Y., Kang, K., Zhang, X., Luo, R., Tu, Z., Zheng, Y., Guo, L., Wang, H., Tang, M., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-33 · Cited by 19
Self-citationLi, Y., Lin, Y., Tang, Y., Jiang, M., Chen, X., Chen, H., Nie, Q., Wu, J., Tong, X., Li, J., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06835-y · Cited by 21
Abudureheman, T., Xia, J., Li, M., Zhou, H., Zheng, W., Zhou, N., Shi, R., Zhu, J., Yang, L., Chen, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663360 · Cited by 18
“These results provide additional evidence that cell cycle progression is inextricably bound up with cellular metabolism, supporting the conclusion that CDK6 and CDK8 play a role in regulating glucose consumption and glycolysis (18, 19).”
BackgroundResultEffect of pH on the structure and function of cyclin-dependent kinase 6
Yousuf, M., Shamsi, A., Anjum, F., Shafie, A., Islam, A., Haque, Q. M. R., Elasbali, A. M., Yadav, D. K., & Hassan, M. I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263693 · Cited by 20
“CDK6 is a key regulator in various cellular processes, such as cell proliferation [6– 8], differentiation [9–11], inflammation [12], apoptosis and cancer [1, 8, 13, 14], suggesting PLOS ONE”
BackgroundCDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer
Hu, J., Shen, J., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109870 · Cited by 18
Zhang, Y., He, L., Huang, L., Yao, S., Lin, N., Li, P., Xu, H., Wu, X., Xu, J., Lü, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.503 · Cited by 18
Activation of miR-500a-3p/CDK6 axis suppresses aerobic glycolysis and colorectal cancer progression
Liu, Y., Tang, W., Ren, L., Liu, T., Yang, M., Wei, Y., Chen, Y., Ji, M., Chen, G., Chang, W., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03308-8 · Cited by 17
“found that CDK6 regulates the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2 [17].”
BackgroundInfluentialF-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression
Li, F., Yu, H., Zhang, Y., Ma, Y., Chen, X., Zhang, J., Sun, L., Guo, R., Wu, Y., Zheng, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59407-9 · Cited by 19
Jiang, N., Chen, Z., Li, B., Guo, S., Li, A., Zhang, T., Fu, X., Si, S., & Cui, Y. (2019) · Precision Radiation Oncology · doi:10.1002/pro6.1074 · Cited by 16
Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts
Soamalala, J., Diot, S., Pellerano, M., Blanquart, C., Galibert, M., Jullian, M., Puget, K., & Morris, M. C. (2020) · ChemBioChem · doi:10.1002/cbic.202000677 · Cited by 17
Patient-derived Enterococcus faecium with inflammatory genotypes promote colitis
Wang, Z., Iida, N., Seishima, J., Okafuji, H., Yutani, M., Fujinaga, Y., Hashimoto, Y., Tomita, H., Mizukoshi, E., & Kaneko, S. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01905-4 · Cited by 21
“Reactive oxygen species (ROS) production was measured using an OxiSelect In vitro ROS/RNS Assay Kit (Cell Biolabs) as previously described [24].”
MethodInhibition of USP10 induces myeloma cell apoptosis by promoting cyclin D3 degradation
Xu, Y., Zeng, K., Ren, Y., Mao, C.-Y., Ye, Y., Zhu, X.-T., Sun, Z., Cao, B., Zhang, Z.-B., Xu, G., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01083-w · Cited by 15
Burris, H. A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1435275 · Cited by 16
“death and preventing regrowth of platinum-resistant cells via multiple mechanisms, including alterations in DNA damage response [79] and cell metabolism pathways [80].”
BackgroundXiang, Y., Liu, C., Chen, L., Li, L., & Huang, Y. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000261 · Cited by 15
Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia
Porazzi, P., Dominici, M. D., Salvino, J. M., & Calabretta, B. (2021) · Genes · doi:10.3390/genes12091355 · Cited by 16
Socha, M. W., Flis, W., Wartęga, M., Szambelan, M., Pietrus, M., & Kazdepka-Ziemińska, A. (2023) · Nutrients · doi:10.3390/nu15143206 · Cited by 20
“This, in turn, increases the concentration of ROS, which may directly activate apoptotic pathways [66].”
BackgroundNon-canonical CDK6 activity promotes cilia disassembly by suppressing axoneme polyglutamylation
He, K., Sun, X., Chen, C., Luc, S., Hao, J., Zhang, Y., Huang, Y., Ji, B., Ku, P.-I., Subramanian, R., et al. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202405170 · Cited by 17
“Function heterogeneity for CDK4 and CDK6 has been documented in a variety of biological scenarios (Grossel and Hinds, 2006; Wang et al., 2017).”
Fbxo7 promotes Cdk6 activity to inhibit PFKP and glycolysis in T cells
Harris, R., Yang, M. H., Schmidt, C., Royet, C., Singh, S., Natarajan, A., Morris, M. C., Frezza, C., & Laman, H. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202203095 · Cited by 15
“Fbxo7 promotes Cdk6-independent ubiquitination and Cdk6-dependent phosphorylation of PFKP Cdk6 phosphorylates PFKP (Wang et al., 2017), and Fbxo7 binds directly to and specifically activates Cdk6 (Laman et al., 2005) and also ubiquitinates PFKP (Fig.”
InfluentialHuang, Z., Hu, H., Xian, T., Xu, Z., Tang, D., Wang, B., & Zhang, Y. (2023) · RSC Advances · doi:10.1039/d2ra05932k · Cited by 14
Glucocorticoid Transiently Upregulates Mitochondrial Biogenesis in the Osteoblast
Hsu, C., Jen, C.-Y., Chen, Y., Peng, S.-Y., Wu, S., & Yao, C. (2020) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_51_20 · Cited by 14
Cerón‐Carrasco, J. P., & Jacquemin, D. (2021) · ChemMedChem · doi:10.1002/cmdc.202100046 · Cited by 13
CDK6 kinase inhibition unmasks metabolic dependencies in BCR::ABL1+ leukemia
Scheiblecker, L., Klampfl, T., Doma, E., Nebenfuehr, S., Torres‐Quesada, O., Strich, S. L., Heller, G., Werdenich, D., Tschulenk, W., Zojer, M., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07434-1 · Cited by 14
“Ordinary one-way ANOVA test multiple comparisons was performed to evaluate statistical signi fi cance between Cdk6 + / + , Cdk6 − / − and Cdk6 KM/KM .”
Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search
Shapiro, G. I. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.013 · Cited by 15
“NRF2 regulates the expression of a vast array of genes, including those for the detoxification of reactive oxygen species (ROS), cellular metabolism, drug detoxification, and other processes (reviewed in Hayes and Dinkova-Kostova, 2014).”
BackgroundInfluentialAn Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
Robert, M., Frenel, J., Bourbouloux, E., Rigaud, D. B., Patsouris, A., Augereau, P., Gourmelon, C., & Campone, M. (2018) · Drugs · doi:10.1007/s40265-018-0972-9 · Cited by 13
Garza‐Aguilar, S. M., Axosco-Marín, J., Lara‐Núñez, A., Guerrero-Molina, E. D., Lemus-Enciso, A. T., García‐Ramírez, E., & Vázquez-Ramos, J. M. (2018) · Plant Science · doi:10.1016/j.plantsci.2018.12.020 · Cited by 13
Song, X., Liao, X.-Y., Zheng, X., Liu, J., Zhang, Z.-W., Zhang, L., & Yan, Y. (2021) · Cancers · doi:10.3390/cancers13040834 · Cited by 13
Chang, M., Huhn, S. C., Nelson, L., Betenbaugh, M. J., & Du, Z. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28050 · Cited by 14
Baig, M. H., Yousuf, M., Khan, M. I., Khan, I., Ahmad, I. S., Alshahrani, M. Y., Hassan, M. I., & Dong, J.-J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.865454 · Cited by 18
Metadata
- Authors
- Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., Keibler, M. A., Sicinska, E., Gerdemann, U., Haining, W. N., Roberts, T. M., Polyak, K., Gygi, S. P., Dyson, N. J., & Sicinski, P.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Massachusetts Institute of Technology (US)
- Dana-Farber Cancer Institute (US)
- Broad Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7658
- Pages
- 426-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5516959
- OpenAlex
- W2624626767
- Cited by
- 347
- References
- 37
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 29 · 2023: 43 · 2022: 41 · 2021: 45 · 2020: 61 · 2019: 32 · 2018: 30 · 2017: 15
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, P50CA090381, F32CA165856, T32CA009361, R01CA202634, P01CA080111, R01CA163698, R01CA083688)
- National Institute of General Medical Sciences (R01GM067945)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin D3, CDK6, cyclin-dependent kinases, tumor cell survival, glycolysis, 6-phosphofructokinase, PKM2, pentose phosphate pathway, serine pathway, NADPH, glutathione, reactive oxygen species, oxidative stress, apoptosis, CDK4/6 inhibitors, RB1, patient selection
- MeSH terms
- Aminopyridines, Animals, Cell Cycle, Cell Survival, Female, Glycolysis, Humans, Neoplasms, Pentose Phosphate Pathway, Phosphofructokinase-1, Phosphorylation, Purines, Pyruvate Kinase, Serine, Apoptosis, Reactive Oxygen Species, Oxidative Stress, Xenograft Model Antitumor Assays, Reactive Nitrogen Species, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Cyclin D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.